SG11201601807XA - Methods for treating chronic obstructive pulmonary disease using benralizumab - Google Patents

Methods for treating chronic obstructive pulmonary disease using benralizumab

Info

Publication number
SG11201601807XA
SG11201601807XA SG11201601807XA SG11201601807XA SG11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA
Authority
SG
Singapore
Prior art keywords
benralizumab
methods
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
SG11201601807XA
Other languages
English (en)
Inventor
Der Merwe Rene Van
Christine Ward
Ubaldo Martin
Lorin Roskos
Bing Wang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201601807XA publication Critical patent/SG11201601807XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201601807XA 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab SG11201601807XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
SG11201601807XA true SG11201601807XA (en) 2016-04-28

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201807318RA SG10201807318RA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab
SG11201601807XA SG11201601807XA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201807318RA SG10201807318RA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (enrdf_load_stackoverflow)
EP (2) EP3485902A1 (enrdf_load_stackoverflow)
JP (3) JP2016534996A (enrdf_load_stackoverflow)
KR (1) KR20160061352A (enrdf_load_stackoverflow)
CN (2) CN113230399A (enrdf_load_stackoverflow)
AU (2) AU2014334563A1 (enrdf_load_stackoverflow)
BR (1) BR112016008082A2 (enrdf_load_stackoverflow)
CA (1) CA2925402A1 (enrdf_load_stackoverflow)
MX (2) MX2016004329A (enrdf_load_stackoverflow)
RU (1) RU2706729C2 (enrdf_load_stackoverflow)
SG (2) SG10201807318RA (enrdf_load_stackoverflow)
WO (1) WO2015057668A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
KR20160104636A (ko) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체
US10479836B2 (en) 2015-06-01 2019-11-19 National University Corporation University Of Toyama Method for treating pulmonary hypertension with interleukin-5 receptor antibody
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
AU2020398168A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods for treating COPD by administering an IL-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811691B1 (en) * 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
EP1914244B1 (en) * 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
AU2001232304A1 (en) * 2000-02-15 2001-08-27 Kyowa Hakko Kogyo Co. Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
CA2685222C (en) * 2007-05-14 2017-12-19 Medimmune, Llc Methods of reducing eosinophil levels
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
CA2814431A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
RU2737245C2 (ru) * 2010-12-16 2020-11-26 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием тн2
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
SG10202005560UA (en) * 2013-08-12 2020-07-29 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
DK3520811T3 (da) * 2013-08-12 2021-03-22 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
DK3536339T3 (da) * 2013-08-12 2021-12-20 Astrazeneca Ab Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Also Published As

Publication number Publication date
BR112016008082A2 (pt) 2017-10-17
RU2016118425A3 (enrdf_load_stackoverflow) 2018-07-19
KR20160061352A (ko) 2016-05-31
US20200123262A1 (en) 2020-04-23
SG10201807318RA (en) 2018-09-27
RU2016118425A (ru) 2017-11-21
JP2016534996A (ja) 2016-11-10
WO2015057668A1 (en) 2015-04-23
AU2020202333A1 (en) 2020-04-23
EP3485902A1 (en) 2019-05-22
US20150104447A1 (en) 2015-04-16
CN113230399A (zh) 2021-08-10
AU2014334563A1 (en) 2016-04-07
CA2925402A1 (en) 2015-04-23
US20180291108A1 (en) 2018-10-11
CN105636607A (zh) 2016-06-01
EP3057609A1 (en) 2016-08-24
MX2016004329A (es) 2016-11-10
MX2019013468A (es) 2020-02-12
EP3057609A4 (en) 2017-03-22
JP6870037B2 (ja) 2021-05-12
US20170107291A1 (en) 2017-04-20
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
JP2021107421A (ja) 2021-07-29

Similar Documents

Publication Publication Date Title
IL274462B (en) Anti-b7–h1 antibodies for the treatment of tumors
IL245193B (en) Thoracoscopic methods for the treatment of bronchial disease
IL243976A0 (en) kdm1a inhibitors for disease treatment
ZA201506401B (en) Process for producing hydrocarbons
SG11201600918PA (en) Method for authenticating transactions
SG11201601807XA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
SG11201508388YA (en) Methods for enhancing aged muscle regeneration
SG11201603050TA (en) Methods for treating cancers
PL3019577T3 (pl) Sposób wytwarzania węglowodorów
IL244042A0 (en) A method for treating leiftic disease
EP2945616A4 (en) TREATMENT OF LUNG DISEASES
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
EP2945593A4 (en) METHOD OF LYOPHILIZATION
SG11201600484TA (en) Methods for improving asthma symptoms using benralizumab
PL3016682T3 (pl) Sposoby leczenia nowotworu
PL2875049T3 (pl) Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
IL233568A0 (en) A method for treating obstructive lung disease
HK1227729A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
LU92721B1 (en) Oral suspension for treating eosinophilic esophagitis
LU92599B1 (en) Oral suspension for treating eosinophilic esophagitis
GB201304811D0 (en) Novel treatment for hypertension
GB201303684D0 (en) Modified cytosine derivatisation process
PL2928461T3 (pl) Leczenie przewlekłej choroby nerek